ImmunityBio (IBRX) 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 10, 2016
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	NK
Entity Registrant Name	NANTKWEST, INC.
Entity Central Index Key	1,326,110
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		81,977,285

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 63,250	$ 175,908
Prepaid expenses and other current assets	3,776	3,322
Marketable securities	158,509	118,310
Total current assets	225,535	297,540
Marketable securities, noncurrent	116,197	55,135
Property and equipment, net	7,156	5,523
Intangible assets, net	6,844	7,292
Other assets	1,696	1,359
Total assets	357,428	366,849
Current liabilities:
Accounts payable	1,105	2,085
Accrued expenses	4,716	2,575
Due to related parties	1,674	1,352
Other current liabilities	363	136
Total current liabilities	7,858	6,148
Build-to-suit liability, less current portion	2,451	2,468
Deferred rent	1,344	845
Deferred revenue	203	228
Deferred tax liability	1,072	1,165
Total liabilities	$ 12,928	$ 10,854
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock	$ 8	$ 8
Additional paid-in capital	625,200	606,555
Accumulated other comprehensive income (loss)	318	(192)
Accumulated deficit	(281,026)	(250,376)
Total stockholders’ equity	344,500	355,995
Total liabilities and stockholders’ equity	$ 357,428	$ 366,849

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - Common Stock Class Undefined - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	81,930,998	81,311,686
Common stock, shares outstanding	81,930,998	81,311,686

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue	$ 6	$ 120
Operating expenses:
Research and development	4,944	603
Selling, general and administrative	26,651	31,618
Total operating expenses	31,595	32,221
Loss from operations	(31,589)	(32,101)
Other income (expense):
Investment income, net	768	32
Change in fair value of warrant liability		(883)
Other income, net	28	104
Total other income (expense)	796	(747)
Loss before income taxes	(30,793)	(32,848)
Income tax (benefit) expense, net	(143)	1
Net loss	$ (30,650)	$ (32,849)
Net loss per share:
Basic and diluted	$ (0.38)	$ (0.54)
Weighted average number of shares during the period:
Basic and diluted	81,574,709	61,137,625

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (30,650)	$ (32,849)
Other comprehensive income, net of income taxes:
Net unrealized gain on available-for-sale securities	517
Reclassification of net realized gains on available-for-sale securities included in net income	(7)
Total other comprehensive income	510
Comprehensive loss	$ (30,140)	$ (32,849)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2015	$ 355,995	$ 8	$ 606,555	$ (192)	$ (250,376)
Beginning Balance, Shares at Dec. 31, 2015		81,311,686
Exercise of stock options	657		657
Exercise of stock options, Shares		917,383
Stock-based compensation expense	20,535		20,535
Exercise of warrants	3		3
Exercise of warrants, Shares		1,929
Repurchase of common stock	$ (2,550)		(2,550)
Repurchase of common stock, Shares	(300,000)	(300,000)
Other comprehensive loss, net	$ 510			510
Net loss	(30,650)				(30,650)
Ending Balance at Mar. 31, 2016	$ 344,500	$ 8	$ 625,200	$ 318	$ (281,026)
Ending Balance, Shares at Mar. 31, 2016		81,930,998

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net loss	$ (30,650)	$ (32,849)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	485	26
Stock-based compensation expense	20,535	24,523
Deferred income tax benefit	(145)
Change in value of warrant liability		883
Non-cash interest items	(295)
Loss incurred by Inex Bio		57
Loss on disposal of assets	15
Amortization of net premiums on marketable securities	426
Gain on sales of marketable securities	(46)
Gain on settlement of note payable		(133)
Changes in operating assets and liabilities:
Accounts receivable		105
Prepaid and other current assets	(160)	71
Other assets	(337)	(87)
Accounts payable	(737)	99
Accrued expenses and other liabilities	1,236	(3)
Due to related parties	322
Deferred rent	500
Deferred revenue	(5)	(64)
Net cash used in operating activities	(8,856)	(7,372)
Investing activities:
Purchases of property and equipment	(1,067)	(38)
Purchase of Inex Bio Inc., net of cash acquired		(1,818)
Purchases of marketable securities	(111,397)
Sales of marketable securities	10,552
Net cash used in investing activities	(101,912)	(1,856)
Financing activities:
Payments on notes payable		(132)
Proceeds from exercise of stock options and warrants	660	110
Repurchase of common stock	(2,550)
Net cash used in financing activities	(1,890)	(22)
Net decrease in cash and cash equivalents	(112,658)	(9,250)
Cash and cash equivalents, beginning of period	175,908	59,104
Cash and cash equivalents, end of period	63,250	49,854
Cash paid during the period for:
Income taxes	1	1
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	1,074
Unrealized gain on marketable securities	$ 796
Inex Bio Inc
Supplemental disclosure of non-cash investing and financing activities:
Issuance of warrants in Inex Bio, Inc. acquisition		$ 5,170

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization NantKwest, Inc. (the Company) was incorporated in Illinois on October 7, 2002 under the name ZelleRx Corporation. On January 22, 2010, the Company changed its name to Conkwest, Inc., and on July 10, 2015, the Company changed its name to NantKwest, Inc. The Company is a biotechnology company headquartered in San Diego, California with certain operations in Culver City, California. The Company is commercially developing targeted direct-acting immunotherapeutic agents for a variety of clinical conditions. The Company holds the exclusive right to commercialize activated natural killer (aNK) cells, a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells. The Company owns corresponding U.S. and foreign composition and methods-of-use patents and applications covering the clinical use of aNK cells as a therapeutic to treat a spectrum of clinical conditions. The Company also licensed exclusive commercial rights to a portfolio of CD16 bearing aNK cells along with the corresponding U.S. and foreign composition and methods-of-use patents and applications covering the non-clinical use in laboratory testing of monoclonal antibodies as well as clinical use as a therapeutic to treat cancers in combination with antibody products. The Company has licensed or sub-licensed its cell lines and intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses. The Company retains exclusive worldwide rights to clinical and research data, intellectual property and know-how developed with the Company’s aNK cells, as well as the only clinical grade master cell bank. Unaudited Interim The accompanying condensed consolidated balance sheet at March 31, 2016, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2016, the condensed consolidated statements of cash flows for the three months ended March 31, 2016, and the condensed consolidated statement of stockholders’ equity for the three months ended March 31, 2016, have been prepared by the management of Company and have not been audited. These financial statements have been prepared on the same basis as the audited consolidated financial statements for the fiscal year ended December 31, 2015 and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the Company’s results for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (GAAP). Principles of Consolidation The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc., and have been prepared in accordance with GAAP. All intercompany amounts have been eliminated. Liquidity As of March 31, 2016, the Company had an accumulated deficit of approximately $281.0 million. The Company also had negative cash flow from operations of approximately $8.9 million during the three months ended March 31, 2016. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents and marketable securities on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents and marketable securities will enable it to fund operations and capital expenditure requirements for at least the next 24 months, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies With the exception of the preclinical and clinical trial accrual policy discussed below, there have been no significant changes to the items that the Company disclosed as its summary of significant accounting policies in the Annual Report on Form 10-K for the year ended December 31, 2015. Preclinical and As part of the process of preparing the financial statements, the Company is required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company estimates clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on the Company’s behalf. In accruing clinical and research related fees, the Company estimates the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, preclinical and clinical trial accruals, and the valuation of build-to-suit lease assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of March 31, 2016 2015 Outstanding options 7,788,883 9,257,996 Outstanding restricted stock units 1,329,438 — Outstanding warrants 17,817,687 22,610,078 Total 26,936,008 31,868,074 Amounts in the table above reflect the common stock equivalents of the noted instruments. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2016-02, or ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Financial Statement Details

Financial Statement Details	3 Months Ended
	Mar. 31, 2016
Financial Statement Details [Abstract]
Financial Statement Details	3. Financial Statement Details Prepaid Expenses and Other Current Assets As of March 31, 2016 and December 31, 2015, prepaid expenses and other current assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Interest receivable - marketable securities $ 1,206 $ 911 Prepaid services 1,182 631 Prepaid license fees 505 101 Prepaid legal fees 350 350 Prepaid insurance 298 466 Due from related parties (Note 7) 45 217 Tax refund receivable — 646 Other 190 — $ 3,776 $ 3,322 Property and Equipment, Net As of March 31, 2016 and December 31, 2015, property and equipment was made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Construction in progress $ 6,753 $ 5,136 Equipment 297 241 Leasehold improvements 182 182 Furniture & fixtures 123 125 Software 4 6 7,359 5,690 Accumulated depreciation (203 ) (167 ) $ 7,156 $ 5,523 Construction in progress includes the estimated fair market value of the building under the Company’s build-to-suit lease for $2.7 million of which the Company is the "deemed owner" for accounting purposes only. See Note 6. Intangible Assets As of March 31, 2016 and December 31, 2015, intangible assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Technology license* $ 8,636 $ 8,636 Less accumulated amortization (1,792 ) (1,344 ) $ 6,844 $ 7,292 *Inclusive of $1.5 million intangible asset related to the deferred tax liability, which is not amortized. Amortization expense was $0.4 million, and $0 for the three months ended March 31, 2016 and 2015, respectively. Amortization for the Company’s technology license is included in research and development expense on the condensed consolidated statement of operations. Other Assets As of March 31, 2016 and December 31, 2015, other assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Equipment not placed in service $ 609 $ 624 License fees 423 — Software license and implementation costs 415 391 Security deposit 249 344 $ 1,696 $ 1,359 Accrued Expenses As of March 31, 2016 and December 31, 2015, accrued expenses were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Accrued bonuses $ 1,801 $ 1,359 Accrued construction costs 992 132 Accrued compensation 828 348 Accrued professional and service fees 702 367 Accrued clinical trials 181 — Accrued franchise and property taxes 81 225 Other 131 144 $ 4,716 $ 2,575 Investment Income, Net Net investment income includes interest income from all bank accounts as well as marketable securities, net realized gains or losses on sales of investments and the amortization of the premiums and discounts of the investments and is as follows for the three months ended March 31, 2016 and 2015 (in thousands). Three Months Ended March 31, 2016 2015 Interest income $ 1,193 $ 32 Investment amortization accretion expense, net (426 ) — Net realized gains on investments 1 — $ 768 $ 32 Interest income includes interest from the Company’s bank deposits. The Company did not recognize an impairment loss on any investments during the three months ended March 31, 2016 and 2015.

Cash Equivalents and Marketable

Cash Equivalents and Marketable Securities	3 Months Ended
	Mar. 31, 2016
Cash Equivalents And Marketable Securities [Abstract]
Cash Equivalents and Marketable Securities	4. Cash Equivalents and Marketable Securities As of March 31, 2016, all of the Company’s marketable securities are classified as available-for-sale and are scheduled to mature within 3.6 years. At March 31, 2016, the detail of the Company’s cash equivalents and marketable securities is as follows (in thousands): March 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current: Commercial paper $ 28,053 $ 17 $ — $ 28,070 Government sponsored securities 37,158 12 — 37,170 Corporate debt securities 111,315 75 (22 ) 111,368 Foreign government bonds 6,911 5 (3 ) 6,913 Current portion 183,437 109 (25 ) 183,521 Noncurrent: Government sponsored securities 17,039 68 — 17,107 Corporate debt securities 94,619 470 (15 ) 95,074 Foreign government bonds 4,009 7 — 4,016 Noncurrent portion 115,667 545 (15 ) 116,197 Total $ 299,104 $ 654 $ (40 ) $ 299,718 The cash equivalent portions included in the current fair values above are $23.0 million and $2.0 million for government sponsored securities and corporate debt securities, respectively. At March 31, 2016, 16 of the securities and bonds are in an unrealized loss position. No securities have been in an unrealized loss position for greater than 12 months. Available-for-sale investments that had been in an unrealized loss position for less than 12 months at March 31, 2016 are as follows (in thousands): March 31, 2016 Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 37,658 $ (37 ) Foreign government bonds 1,894 (3 ) Total $ 39,552 $ (40 ) The Company evaluated its securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Therefore, the Company did not recognize any other-than-temporary impairment loss during the three months ended March 31, 2016.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements In accordance with the authoritative guidance for financial assets and liabilities measured at fair value on a recurring basis (ASC Topic 820), the Company prioritizes the inputs used to measure fair value from market-based assumptions to entity specific assumptions as follows: · Level 1—Inputs based on quoted market prices for identical assets or liabilities in active markets at the measurement date. · Level 2—Observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3— Inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instruments valuation. The following table presents the Company’s hierarchy for its assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015: Fair Value Measurements at March 31, 2016 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 25,011 $ — $ 25,011 $ — Commercial paper 28,070 — 28,070 — Government sponsored securities 14,159 — 14,159 — Corporate debt securities 109,368 — 109,368 — Foreign government bonds 6,913 — 6,913 — Noncurrent: Government sponsored securities 17,107 — 17,107 — Corporate debt securities 95,074 — 95,074 — Foreign government bonds 4,016 — 4,016 — Total assets measured at fair value $ 299,718 $ — $ 299,718 $ — *This amount excludes $38.2 million in depository institutions which are classified as Level 1 assets. Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 18,039 $ — $ 18,039 $ — Commercial paper 24,917 — 24,917 — Corporate debt securities 86,450 — 86,450 — Foreign government bonds 6,943 — 6,943 — Noncurrent: Corporate debt securities 51,131 — 51,131 — Foreign government bonds 4,004 — 4,004 — Total assets measured at fair value $ 191,484 $ — $ 191,484 $ — *This amount excludes $157.9 million in depository institutions which are classified as Level 1 assets.

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	6. Commitments and Contingencies Contingencies In March 2009, the Company received a final rejection in one of the Company’s original patent applications pertaining to certain limited methods of use claims for NK-92 from the U.S. Patent and Trademark Office (the USPTO) (but the USPTO allowed claims on all of the other proposed claims, including other methods of use). The Company appealed this decision with the USPTO Board of Appeals and, in the fall of 2013, the Board of Appeals reversed the Examiner’s rejection of the claim to certain limited methods of use with NK-92, but affirmed the Examiner’s rejection of the remaining patent claims. In December 2013, the Company brought an action in the U.S. District Court for the Eastern District of Virginia to review the decision of the USPTO as the Company disagreed with the decision as to the certain limited non-allowed claims. On September 2, 2015, the U.S. District Court granted the USPTO’s motion for summary judgment. The Company is in the process of appealing the decision. Based on the information available at present, the Company cannot reasonably estimate a range of loss for this action. Accordingly, no liability associated with this action has been accrued. The Company is expensing legal costs associated with defending this litigation as the costs are incurred. Securities Litigation In March 2016, a securities class action complaint was filed in federal district court in California against the Company related to the recently announced restatement of certain interim financial statements for the periods ended June 30, 2015 and September 30, 2015. The case, Sudunagunta v. NantKwest, Inc., et al Contractual Obligations - Leases The Company leases: (i) office space in Cardiff-by-the-Sea, California; (ii) a research facility in Boston, Massachusetts on a month-to-month basis; (iii) a research facility in Woburn, Massachusetts (discussed further below) that will replace the Boston facility once it is ready for occupation; (iv) office space in Cary, North Carolina; (iv) a research and manufacturing facility in San Diego, California and; (v) office and research space in Culver City, California from a related party (Note 7). In March 2016, the Company entered into a lease agreement for an approximately 7,893 square foot facility in Woburn, Massachusetts for a research and development laboratory, related office and other related uses. The base rent is $0.2 million per year with a $1 per square foot annual increase on each anniversary date. In March 2016, the Company extended the lease on the Cardiff-by-the-Sea, California office space until August 31, 2018. The current annual lease payment is $0.1 million, which will increase to $0.2 million and $0.2 million at September 1, 2016 and 2017, respectively. In November 2015, the Company entered into a facility license agreement with NantWorks, LLC (NantWorks), a related party, for office space in Culver City, California, which is to be converted to a research and development laboratory and a Good Manufacturing Practices (GMP) laboratory. The license was effective in May 2015 and extends through December 2020. The annual license fee is $0.6 with annual increases of 3% beginning in January 2017. The Company is responsible for costs to build out the laboratory and has incurred costs of approximately $3.2 million as of March 31, 2016, which is reflected in construction in progress on the condensed consolidated balance sheet. Additionally, in order for the facility to meet the Company's research and development and GMP laboratory specifications, the Company made structural changes as part of the conversion from office to laboratory space, and as a result, the Company has concluded that it was the “deemed owner” of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded a non-cash build-to-suit lease asset of $2.7 million, representing its estimate of the fair market value of the building, and a corresponding construction build-to-suit lease liability, recorded as a component of other current and non-current liabilities on the condensed consolidated balance sheet as of March 31, 2016. Upon completion of construction of this facility, the Company will evaluate the de-recognition of the asset and liability under the provisions of ASC Subtopic 840-40, Leases - Sale-Leaseback Transactions. However, if the Company does not comply with the provisions needed for sale-leaseback accounting, the lease will be accounted for as a financing obligation and lease payments will be attributed to (1) a reduction of the principal financing obligation; (2) imputed interest expense; and (3) land lease expense (which is considered an operating lease and a component of research and development expenses) representing an imputed cost to lease the underlying land of the facility. In addition, the underlying building asset will be depreciated over the building's estimated useful life which is estimated at 39 years. At the conclusion of the lease term, the Company would de-recognize both the net book values of the asset and financing obligation. The Company recognizes rent expense under its operating leases on a straight-line basis. Rent expense for the three months ended March 31, 2016 and 2015 was $0.7 million and $0.1 million, respectively. Commitments The Company has not entered into any new significant contracts during the three months ended March 31, 2016.

Related Party Agreements

Related Party Agreements	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Agreements	7. Related Party Agreements The Company’s chairman and CEO founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. The Company has entered into arrangements with NantWorks and certain affiliates of NantWorks, as described below, to facilitate the development of new genetically modified NK cells for the Company’s product pipeline. In March 2016, NantBioScience, Inc. (NantBioScience), a NantWorks company, and the National Cancer Institute entered into a cooperative research and development agreement. The agreement covers NantBioScience and its affiliates, including the Company. Under the agreement, the parties will collaborate on the preclinical and clinical development of proprietary recombinant NK cells and monoclonal antibodies in monotherapy and in combination immunotherapies. The Company expects to benefit from the preclinical and clinical research conducted during the first year under this agreement and is providing the first year of funding under the five-year agreement. In April 2016, the Company paid $0.6 million to the National Cancer Institute as a prepayment for this first year of funding. The Company will recognize research and development expense ratably over a 12-month period. Under the NantWorks shared services agreement executed in November 2015, but effective May 2015, NantWorks provides corporate, general and administrative, manufacturing strategy, regulatory and clinical trial strategy and other support services, and the Company is charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. For the three months ended March 31, 2016, the Company recorded $0.8 million to selling, general and administrative expense and $0.3 million to research and development expense under this arrangement on the condensed consolidated statement of operations. The Company owed NantWorks $1.5 million for all agreements between the two affiliates at March 31, 2016, which is included in due to related parties on the condensed consolidated balance sheet. Under the November 2015 facility license agreement with NantWorks for office and laboratory space, the Company recorded rent expense of $0.1 million for the three months ended March 31, 2016, which is included in research and development expense on the condensed consolidated statement of operations. The Company is responsible for costs to build out the laboratory and has incurred costs of approximately $3.2 million as of March 31, 2016, which is reflected in property and equipment, net on the condensed consolidated balance sheet. Under the June 2015 agreement with NantOmics, LLC (NantOmics) to obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics, the Company incurred $0.1 million of cost in the three months ended March 31, 2016, which is shown as research and development expense on the condensed consolidated statement of operations. The Company is obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five years and renews automatically for successive one year periods, unless terminated earlier. The Company owed NantOmics $0.2 million at March 31, 2016, which is included in due to related parties on the condensed consolidated balance sheet.

Spinout of Brink Biologics and

Spinout of Brink Biologics and Coneksis	3 Months Ended
	Mar. 31, 2016
Spinout
Spinout of Brink Biologics and Coneksis	8. Spinout of Brink Biologics and Coneksis On June 9, 2015, the Company spun out its business related to testing and diagnostic products and services into the entity, Brink Biologics, Inc. (Brink Biologics) in exchange for all of the issued and outstanding shares of Brink Biologics which were subsequently distributed by a dividend to the Company’s stockholders. Under the spin-out arrangement, the Company transferred to Brink Biologics all of the Company’s existing revenue-earning, non-exclusive license agreements that allow third parties to use the Company’s cell lines and intellectual property for non-clinical laboratory testing. In addition, the Company transferred or licensed to Brink Biologics the Company’s other assets associated with testing and diagnostics products and services. The Company granted to Brink Biologics worldwide, exclusive licenses to the use of certain cell lines limited to the field of in vitro in vivo On June 9, 2015, the Company spun out its business related to veterinary oncology into the entity, Coneksis in exchange for all of the issued and outstanding shares of Coneksis which were subsequently distributed by a dividend to our stockholders. In connection with the spin-out arrangement, the Company granted to Coneksis worldwide, exclusive licenses for use of certain cell lines in the field of veterinary medical research and therapeutics, trademarks, intellectual property, and patents, including the Company’s rights under its license agreement with Fox Chase Cancer Center. As part of the agreement, the Company also has a non-exclusive license to any results and data arising from Coneksis’ use of the Company’s cell lines and intellectual property for the Company’s use for internal research purposes and outside of Coneksis’ field. In consideration for the license grants, Coneksis is obligated to pay the Company a single-digit royalty on amounts received for the sale of licensed products and services, as well as a single-digit percentage share of other revenue received by Coneksis from the grant of sublicenses under the Company’s rights. Coneksis and the Company have the right to terminate the license agreement under certain conditions. Also, as part of the spin-out arrangement, the Company has agreed to provide certain services to Coneksis for a transitional period on a fee-for-service basis. For the three months ended March 31, 2016, the Company recorded $1,500 for services provided to Coneksis, which is included in other income on the condensed consolidated statement of operations. At March 31, 2016, Coneksis owes the Company $8,000, which has been fully reserved. The Company determined it has a variable interest in both Brink Biologics and Coneksis through its royalty agreements. Based upon the level of equity investment at risk, Brink Biologics and Coneksis are considered variable interest entities (VIEs). The Company considered whether it is the primary beneficiary of the Brink Biologics and Coneksis VIEs and required to consolidate the entities. As the Company does not control the research and development or the sales of the potential licensed or commercialized products, the Company does not direct the activities of Brink Biologics and Coneksis that most significantly impact their economic performance. Therefore, the Company determined that it is not the primary beneficiary of the entities and does not consolidate the Brink Biologics VIE and the Coneksis VIE.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Stock Repurchase— In November 2015, the board of directors approved a share repurchase program (2015 Share Repurchase Program) allowing the CEO or CFO, on behalf of the Company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0 million of the Company’s outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases will be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company expects to finance the purchases with existing cash balances. During the three months ended March 31, 2016, 300,000 shares were repurchased at $8.50 per share for a total of $2.6 million. There were no commissions as it was a private repurchase at the then current market price. At March 31, 2016, $47.4 million remained authorized for repurchase under the Company’s 2015 Share Repurchase Program.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation Stock-Based Compensation The following table presents stock-based compensation included on the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2016 2015 Stock-based compensation expense: Warrants for Class A common stock to an officer $ 12,090 $ — Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition — 22,747 Employee stock options 4,893 1,088 Non-employee stock options — 688 Employee restricted stock units 3,365 — Non-employee restricted stock units 187 — $ 20,535 $ 24,523 Stock-based compensation expense in operating expenses: Research and development $ 262 $ 189 Selling, general and administrative 20,273 24,334 $ 20,535 $ 24,523 Stock Options The following table summarizes stock option activity under the equity incentive plans for the three months ended March 31, 2016 (in thousands, except for share and per share amounts): Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2015 8,777,893 $ 5.36 $ 116,273 7.2 Options forfeited (71,627 ) $ 2.00 Options exercised (917,383 ) $ 1.21 Outstanding at March 31, 2016 7,788,883 $ 5.87 $ 42,691 6.8 Vested and Exercisable at March 31, 2016 4,844,757 The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2016 was $7.0 million. The total unrecognized compensation cost related to non-vested stock options as of March 31, 2016 is $18.9 million, which is expected to be recognized over a weighted-average period of 2.1 years. Restricted Stock Units The following table summarizes the activity for restricted stock units under the 2015 Plan: Number of Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value Unvested balance at December 31, 2015 1,129,638 $ 20.51 Granted 234,800 $ 8.60 Forfeited (35,000 ) $ 17.13 Unvested balance at March 31, 2016 1,329,438 $ 18.50 In March 2016, the Company granted 234,800 shares of restricted stock units of which 169,800 were granted to employees of the Company and 65,000 were granted to employees of related companies under the Company’s shared services agreement with NantWorks (Note 7). As of March 31, 2016, there was $12.2 million of unrecognized stock-based compensation expense related to restricted stock units that is expected to be recognized over a weighted-average period of 1.9 years. Of that amount, $9.0 million of unrecognized expense is related to employee grants with a weighted-average period of 1.3 years and $3.2 million of unrecognized expense is related to non-employee grants with a weighted-average period of 3.6 years and is impacted by periodic mark-to-market adjustments. Warrants The following table summarizes the warrant activity for the three months ended March 31, 2016: Outstanding at December 31, 2015 17,819,616 Warrants exercised (1,929 ) Outstanding at March 31, 2016 17,817,687 Vested and exercisable at March 31, 2016 10,553,550

Acquisition of Inex Bio, Inc

Acquisition of Inex Bio, Inc	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisition of Inex Bio, Inc	11. Acquisition of Inex Bio, Inc. In April 2012, the Company made a strategic decision to enter into a License Agreement with Inex Bio, Inc. (Inex Bio), a Republic of Korea corporation (the Inex License Agreement). Under the Inex License Agreement, the Company provided Inex Bio with an exclusive license to the Company’s technology to be used in products only in certain Asian countries. In exchange for the Inex License Agreement, the Company received a $0.3 million up-front license fee. In addition, the Company was eligible to receive milestone payments of up to $0.8 million based upon completion of clinical trials and a 5% royalty on net sales of applicable products using the aNK cells. No milestone payments were due or received for the three months ended March 31, 2015. In May 2012, the Company acquired 57,000 shares of Inex Bio for $0.2 million, which represented 22.2% of the outstanding shares and 17.4% of the fully-diluted shares of Inex Bio. The Company accounted for its investment under the equity method. The Company reviewed its investment for impairment in accordance with ASC Topic 320, Investments—Debt and Equity Securities. In February and March 2015, InexBio Holdings, LLC (Holdings), an entity owned 50% by Cambridge Equities, L.P., an entity in which the Company’s CEO is the sole member of its general partner, and 50% Eragon Ventures, LLC, an entity of which one of the Company’s former directors is managing member, acquired 220,000 shares or 67.3% of Inex Bio from third party owners for $1.1 million. On March 30, 2015, the Company entered into a Stock Purchase Agreement with Holdings and the third party owners, pursuant to which the Company acquired all the remaining outstanding shares of Inex Bio not previously held by the Company. The Company paid to the other owners of Inex Bio cash of $1.5 million and issued warrants to acquire 593,072 shares of the Company’s Class A common stock at an exercise price of $2.00 per share. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. This resulted in a total fair value of the warrants of $5.2 million. In April 2015, the Company received $1.2 million for the full exercise of the warrants. The Company recorded the transaction as an asset purchase because Inex Bio was a shell corporation without any employees or other significant assets and did not meet the definition of a business under ASC Topic 805, Business Combinations. The purchase price paid to acquire Inex Bio from the other owners is as follows (in thousands): Consideration Total Cash paid by InexBio Holdings, LLC $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752 The following table summarizes the assets acquired and liabilities assumed (in thousands): Cash $ 763 Intangible assets—reacquired rights of Company technology* 8,636 Other assets 42 Investment in Inex Bio (221 ) Deferred tax liability (1,467 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752 * Inclusive of $1.5 million intangible asset related to deferred tax liability. The license solely covers pending patent applications at this time. The Company will amortize the intangible assets over 4 years, which represents the period until the next action date of the pending patent application in the territory of the license issued to Inex Bio. The Company paid Holdings cash of $6.5 million and issued warrants to acquire 2,609,520 shares of the Company’s Class A common stock at an exercise price of $2.00 per share for its assistance in negotiating the acquisition of Inex Bio from the other owners. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. This resulted in a fair value of total warrants of $22.7 million. In April 2015, the Company received $5.2 million for the full exercise of the warrants. The following summarizes the net consideration paid to Holdings (in thousands): Consideration Total Cash $ 6,518 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,165 The Company recorded compensation expense for the portion of the cash and warrants issued to Holdings that exceeded the fair value of the shares acquired consistent with ASC Topic 718. The Company recorded $22.7 million of stock-based compensation and $5.4 million of cash compensation to the Company’s chief executive officer and the former director as a result of acquiring their interest in Inex Bio.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The difference between the federal statutory tax rate of 34% and the Company’s 0% tax rate is due to losses in jurisdictions that the Company cannot benefit. Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. The Company then records a related tax benefit in continuing operations. During the three months ended March 31, 2016, the Company recorded unrealized gains on its marketable securities in other comprehensive income, net of taxes. As a result, for the three months ended March 31, 2016 and 2015, respectively, the Company recorded a $52,000 and $0 tax benefit on the condensed consolidated statement of operations and $0.3 million and $0 in other comprehensive income. The Company is operating in Korea. During the three months ended March 31, 2016 and 2015, the tax benefit related to Korea is $0.1 million and $0, respectively. The Company currently files federal and state income tax returns in the United States and in Korea. Income tax expense consists of U.S. federal, state, and Korean income taxes. To date, the Company has not been required to pay U.S. federal income taxes because of current and accumulated net operating losses.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc., and have been prepared in accordance with GAAP. All intercompany amounts have been eliminated.
Liquidity	Liquidity As of March 31, 2016, the Company had an accumulated deficit of approximately $281.0 million. The Company also had negative cash flow from operations of approximately $8.9 million during the three months ended March 31, 2016. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents and marketable securities on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents and marketable securities will enable it to fund operations and capital expenditure requirements for at least the next 24 months, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Preclinical and Clinical Trial Accruals	Preclinical and As part of the process of preparing the financial statements, the Company is required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company estimates clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on the Company’s behalf. In accruing clinical and research related fees, the Company estimates the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, preclinical and clinical trial accruals, and the valuation of build-to-suit lease assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Basic and Diluted Net Loss Per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of March 31, 2016 2015 Outstanding options 7,788,883 9,257,996 Outstanding restricted stock units 1,329,438 — Outstanding warrants 17,817,687 22,610,078 Total 26,936,008 31,868,074 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2016-02, or ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Securities Excluded from the Computation of Potentially Dilutive Securities	The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of March 31, 2016 2015 Outstanding options 7,788,883 9,257,996 Outstanding restricted stock units 1,329,438 — Outstanding warrants 17,817,687 22,610,078 Total 26,936,008 31,868,074 Amounts in the table above reflect the common stock equivalents of the noted instruments.

Financial Statement Details (Ta

Financial Statement Details (Tables)	3 Months Ended
	Mar. 31, 2016
Financial Statement Details [Abstract]
Prepaid expenses and other current assets	As of March 31, 2016 and December 31, 2015, prepaid expenses and other current assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Interest receivable - marketable securities $ 1,206 $ 911 Prepaid services 1,182 631 Prepaid license fees 505 101 Prepaid legal fees 350 350 Prepaid insurance 298 466 Due from related parties (Note 7) 45 217 Tax refund receivable — 646 Other 190 — $ 3,776 $ 3,322
Property and Equipment	As of March 31, 2016 and December 31, 2015, property and equipment was made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Construction in progress $ 6,753 $ 5,136 Equipment 297 241 Leasehold improvements 182 182 Furniture & fixtures 123 125 Software 4 6 7,359 5,690 Accumulated depreciation (203 ) (167 ) $ 7,156 $ 5,523
Intangible Assets	As of March 31, 2016 and December 31, 2015, intangible assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Technology license* $ 8,636 $ 8,636 Less accumulated amortization (1,792 ) (1,344 ) $ 6,844 $ 7,292 *Inclusive of $1.5 million intangible asset related to the deferred tax liability, which is not amortized.
Other Assets	As of March 31, 2016 and December 31, 2015, other assets were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Equipment not placed in service $ 609 $ 624 License fees 423 — Software license and implementation costs 415 391 Security deposit 249 344 $ 1,696 $ 1,359
Accrued Expenses	As of March 31, 2016 and December 31, 2015, accrued expenses were made up of (in thousands): March 31, 2016 December 31, 2015 (Unaudited) Accrued bonuses $ 1,801 $ 1,359 Accrued construction costs 992 132 Accrued compensation 828 348 Accrued professional and service fees 702 367 Accrued clinical trials 181 — Accrued franchise and property taxes 81 225 Other 131 144 $ 4,716 $ 2,575
Investment Income, Net	Net investment income includes interest income from all bank accounts as well as marketable securities, net realized gains or losses on sales of investments and the amortization of the premiums and discounts of the investments and is as follows for the three months ended March 31, 2016 and 2015 (in thousands). Three Months Ended March 31, 2016 2015 Interest income $ 1,193 $ 32 Investment amortization accretion expense, net (426 ) — Net realized gains on investments 1 — $ 768 $ 32

Cash Equivalents and Marketab23

Cash Equivalents and Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2016
Cash Equivalents And Marketable Securities [Abstract]
Schedule of Cash Equivalents and Marketable Securities Available-for-Sale	At March 31, 2016, the detail of the Company’s cash equivalents and marketable securities is as follows (in thousands): March 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current: Commercial paper $ 28,053 $ 17 $ — $ 28,070 Government sponsored securities 37,158 12 — 37,170 Corporate debt securities 111,315 75 (22 ) 111,368 Foreign government bonds 6,911 5 (3 ) 6,913 Current portion 183,437 109 (25 ) 183,521 Noncurrent: Government sponsored securities 17,039 68 — 17,107 Corporate debt securities 94,619 470 (15 ) 95,074 Foreign government bonds 4,009 7 — 4,016 Noncurrent portion 115,667 545 (15 ) 116,197 Total $ 299,104 $ 654 $ (40 ) $ 299,718
Available-for-Sale Investments in Unrealized Loss Position	Available-for-sale investments that had been in an unrealized loss position for less than 12 months at March 31, 2016 are as follows (in thousands): March 31, 2016 Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 37,658 $ (37 ) Foreign government bonds 1,894 (3 ) Total $ 39,552 $ (40 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015: Fair Value Measurements at March 31, 2016 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 25,011 $ — $ 25,011 $ — Commercial paper 28,070 — 28,070 — Government sponsored securities 14,159 — 14,159 — Corporate debt securities 109,368 — 109,368 — Foreign government bonds 6,913 — 6,913 — Noncurrent: Government sponsored securities 17,107 — 17,107 — Corporate debt securities 95,074 — 95,074 — Foreign government bonds 4,016 — 4,016 — Total assets measured at fair value $ 299,718 $ — $ 299,718 $ — *This amount excludes $38.2 million in depository institutions which are classified as Level 1 assets. Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 18,039 $ — $ 18,039 $ — Commercial paper 24,917 — 24,917 — Corporate debt securities 86,450 — 86,450 — Foreign government bonds 6,943 — 6,943 — Noncurrent: Corporate debt securities 51,131 — 51,131 — Foreign government bonds 4,004 — 4,004 — Total assets measured at fair value $ 191,484 $ — $ 191,484 $ — *This amount excludes $157.9 million in depository institutions which are classified as Level 1 assets.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation Expenses Included in Operations Statement	The following table presents stock-based compensation included on the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2016 2015 Stock-based compensation expense: Warrants for Class A common stock to an officer $ 12,090 $ — Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition — 22,747 Employee stock options 4,893 1,088 Non-employee stock options — 688 Employee restricted stock units 3,365 — Non-employee restricted stock units 187 — $ 20,535 $ 24,523 Stock-based compensation expense in operating expenses: Research and development $ 262 $ 189 Selling, general and administrative 20,273 24,334 $ 20,535 $ 24,523
Summarizes Stock Option Activity Under Equity Intensive Plan	The following table summarizes stock option activity under the equity incentive plans for the three months ended March 31, 2016 (in thousands, except for share and per share amounts): Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2015 8,777,893 $ 5.36 $ 116,273 7.2 Options forfeited (71,627 ) $ 2.00 Options exercised (917,383 ) $ 1.21 Outstanding at March 31, 2016 7,788,883 $ 5.87 $ 42,691 6.8 Vested and Exercisable at March 31, 2016 4,844,757
Restricted Stock Units Activity	The following table summarizes the activity for restricted stock units under the 2015 Plan: Number of Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value Unvested balance at December 31, 2015 1,129,638 $ 20.51 Granted 234,800 $ 8.60 Forfeited (35,000 ) $ 17.13 Unvested balance at March 31, 2016 1,329,438 $ 18.50
Summary of Warrant Activity	The following table summarizes the warrant activity for the three months ended March 31, 2016: Outstanding at December 31, 2015 17,819,616 Warrants exercised (1,929 ) Outstanding at March 31, 2016 17,817,687 Vested and exercisable at March 31, 2016 10,553,550

Acquisition of Inex Bio, Inc (T

Acquisition of Inex Bio, Inc (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Purchase Price Paid to Inex Bio	The following summarizes the net consideration paid to Holdings (in thousands): Consideration Total Cash $ 6,518 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,165
Summary of Assets and Liabilities Assumed	The following table summarizes the assets acquired and liabilities assumed (in thousands): Cash $ 763 Intangible assets—reacquired rights of Company technology* 8,636 Other assets 42 Investment in Inex Bio (221 ) Deferred tax liability (1,467 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752 * Inclusive of $1.5 million intangible asset related to deferred tax liability.
Inex Bio Inc
Summary of Purchase Price Paid to Inex Bio	The purchase price paid to acquire Inex Bio from the other owners is as follows (in thousands): Consideration Total Cash paid by InexBio Holdings, LLC $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752

Description of Business and B27

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ (281,026)		$ (250,376)
Net cash used in operating activities	$ (8,856)	$ (7,372)

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	26,936,008	31,868,074
Employee Stock Option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,788,883	9,257,996
Outstanding Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,329,438
Outstanding Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	17,817,687	22,610,078

Financial Statement Details - P

Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Interest receivable - marketable securities	$ 1,206	$ 911
Prepaid services	1,182	631
Prepaid license fees	505	101
Prepaid legal fees	350	350
Prepaid insurance	298	466
Due from related parties (Note 7)	45	217
Tax refund receivable		646
Other	190
Prepaid expenses and other current assets	$ 3,776	$ 3,322

Financial Statement Details -30

Financial Statement Details - Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,359	$ 5,690
Accumulated depreciation	(203)	(167)
Property and equipment, net	7,156	5,523
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,753	5,136
Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	297	241
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	182	182
Furniture And Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	123	125
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4	$ 6

Financial Statement Details - A

Financial Statement Details - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Financial Statement Details [Line Items]
Impairment losses on recognized investments	$ 0	$ 0
Technology License
Financial Statement Details [Line Items]
Amortization expense	400,000	$ 0
NantWorks
Financial Statement Details [Line Items]
Non cash build to suit lease asset	$ 2,700,000

Financial Statement Details - I

Financial Statement Details - Intangible Assets (Detail) - Technology License - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Finite Lived Intangible Assets [Line Items]
Total intangible assets	$ 8,636	$ 8,636
Less accumulated amortization	(1,792)	(1,344)
Intangible assets, net	$ 6,844	$ 7,292

Financial Statement Details -33

Financial Statement Details - Intangible Assets (Parenthetical) (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Mar. 31, 2015
Technology License
Finite Lived Intangible Assets [Line Items]
Intangible asset related to deferred tax liability	$ 1.5	$ 1.5

Financial Statement Details - O

Financial Statement Details - Other Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Equipment not placed in service	$ 609	$ 624
License fees	423
Software license and implementation costs	415	391
Security deposit	249	344
Other Assets Noncurrent	$ 1,696	$ 1,359

Financial Statement Details -35

Financial Statement Details - Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Accrued bonuses	$ 1,801	$ 1,359
Accrued construction costs	992	132
Accrued compensation	828	348
Accrued professional and service fees	702	367
Accrued clinical trials	181
Accrued franchise and property taxes	81	225
Other	131	144
Accrued Liabilities Current	$ 4,716	$ 2,575

Financial Statement Details -36

Financial Statement Details - Investment Income, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Financial Statement Details [Abstract]
Interest income	$ 1,193	$ 32
Investment amortization accretion expense, net	(426)
Net realized gains on investments	1
Investment income, net	$ 768	$ 32

Cash Equivalents and Marketab37

Cash Equivalents and Marketable Securities - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)Security
Schedule Of Available For Sale Securities [Line Items]
Available for sale securities maturity period	3 years 7 months 6 days
Maximum
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, period of unrealized loss positions	12 months
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Cash equivalent portions included in current fair values	$ 2
Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Number of available-for-sale securities in unrealized loss positions | Security	16
Government Sponsored Securities
Schedule Of Available For Sale Securities [Line Items]
Cash equivalent portions included in current fair values	$ 23

Cash Equivalents and Marketab38

Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities Available-for-Sale (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 299,104
Unrealized Gains	654
Unrealized Losses	(40)
Fair Value	299,718
Current Assets
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	183,437
Unrealized Gains	109
Unrealized Losses	(25)
Fair Value	183,521
Current Assets | Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	28,053
Unrealized Gains	17
Fair Value	28,070
Current Assets | Government Sponsored Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	37,158
Unrealized Gains	12
Fair Value	37,170
Current Assets | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	111,315
Unrealized Gains	75
Unrealized Losses	(22)
Fair Value	111,368
Current Assets | Foreign Government Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,911
Unrealized Gains	5
Unrealized Losses	(3)
Fair Value	6,913
Noncurrent Assets
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	115,667
Unrealized Gains	545
Unrealized Losses	(15)
Fair Value	116,197
Noncurrent Assets | Government Sponsored Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	17,039
Unrealized Gains	68
Fair Value	17,107
Noncurrent Assets | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	94,619
Unrealized Gains	470
Unrealized Losses	(15)
Fair Value	95,074
Noncurrent Assets | Foreign Government Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,009
Unrealized Gains	7
Fair Value	$ 4,016

Cash Equivalents and Marketab39

Cash Equivalents and Marketable Securities - Available-for-Sale Investments in Unrealized Loss Position (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	$ 39,552
Available for Sale Investments, Gross Unrealized Losses	(40)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	37,658
Available for Sale Investments, Gross Unrealized Losses	(37)
Foreign Government Bonds
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	1,894
Available for Sale Investments, Gross Unrealized Losses	$ (3)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 299,718	$ 191,484
Current Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	6,913	6,943
Current Assets | Cash and cash equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	25,011	18,039
Current Assets | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	28,070	24,917
Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	109,368	86,450
Current Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	14,159
Noncurrent Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,016	4,004
Noncurrent Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	95,074	51,131
Noncurrent Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	17,107
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	299,718	191,484
Level 2 | Current Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	6,913	6,943
Level 2 | Current Assets | Cash and cash equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	25,011	18,039
Level 2 | Current Assets | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	28,070	24,917
Level 2 | Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	109,368	86,450
Level 2 | Current Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	14,159
Level 2 | Noncurrent Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,016	4,004
Level 2 | Noncurrent Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	95,074	$ 51,131
Level 2 | Noncurrent Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 17,107

Fair Value Measurements - Sum41

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash in depository institutions	$ 38.2	$ 157.9

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)ft²$ / ft²	Mar. 31, 2015USD ($)	Sep. 01, 2017USD ($)	Sep. 01, 2016USD ($)
Commitments And Contingencies [Line Items]
Rent expense	$ 700,000	$ 100,000
NantWorks
Commitments And Contingencies [Line Items]
Period of agreement	The license was effective in May 2015 and extends through December 2020. The annual license fee is $0.6 with annual increases of 3% beginning in January 2017.
Annual license fee	$ 600
Percentage of annual increase of base rent	3.00%
Annual percentage increases to base rent commencement date	Jan. 31, 2017
Costs incurred	$ 3,200,000
Non cash build to suit lease asset	$ 2,700,000
Property and equipment estimated useful lives	39 years
Woburn, Massachusetts
Commitments And Contingencies [Line Items]
Number of square foot of facility leased. | ft²	7,893
Annual percentage increases to base rent commencement date	Apr. 29, 2016
Base rent - yearly	$ 200,000
Annual increase of base rent | $ / ft²	1
Period of agreement	The base rent is $0.2 million per year with a $1 per square foot annual increase on each anniversary date.
Commitment Cardiff By Sea
Commitments And Contingencies [Line Items]
Lease Expiration Date	Aug. 31, 2018
Annual lease payment	$ 100,000
Commitment Cardiff By Sea | Scenario Forecast
Commitments And Contingencies [Line Items]
Annual lease payment			$ 200,000	$ 200,000

Related Party Agreements - Addi

Related Party Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Research and development		$ 4,944	$ 603
Selling, general and administrative		26,651	$ 31,618
Due to related parties		$ 1,674		$ 1,352
NantBioScience
Related Party Transaction [Line Items]
Research and development expense, ratable payment period		12 months
NantBioScience | Subsequent Event
Related Party Transaction [Line Items]
Research and development	$ 600
NantWorks
Related Party Transaction [Line Items]
Due to related parties		$ 1,500
Costs incurred		3,200
NantWorks | Research and Development
Related Party Transaction [Line Items]
Rent expense		100
NantWorks | Shared Services Agreement
Related Party Transaction [Line Items]
Research and development		300
NantWorks | As Adjusted | Shared Services Agreement
Related Party Transaction [Line Items]
Selling, general and administrative		800
NantOmics
Related Party Transaction [Line Items]
Research and development		100
Due to related parties		$ 200
Initial term of agreement entered into with the related party by the entity		5 years
Related party, agreement renewal term		1 year

Spinout of Brink Biologics an44

Spinout of Brink Biologics and Coneksis - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Amount owed to the company	$ 45,000	$ 217,000
Brink Biologics Inc | Spinout
Related Party Transaction [Line Items]
Royalty revenue	1,400
Revenue from services	7,000
Coneksis | Spinout
Related Party Transaction [Line Items]
Revenue from services	1,500
Amount owed to the company	$ 8,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Nov. 30, 2015
Equity [Abstract]
Total amount authorized for repurchase		$ 50,000,000
Repurchase of common stock, shares	300,000
Repurchase of common stock, par value	$ 8.50
Repurchase of common stock, value	$ 2,550,000
Remained authorized shares for repurchase	$ 47,400,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 20,535	$ 24,523
Warrants For Class A Common Stock | Officer
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	12,090
Warrants For Class A Common Stock | Director Related to Inex Bio, Inc
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		22,747
Employee Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	4,893	1,088
Non Employee Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		688
Employee Restricted Stock Units | Employees Of Related Company
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,365
Non Employee Restricted Stock Units
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	187
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	262	189
Selling, General and Administrative | Employee And Non Employee
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 20,273	$ 24,334

Stock-Based Compensation - St47

Stock-Based Compensation - Stock Option Activity (Detail) - Employee Stock Option - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Number of Shares
Stock Options, Beginning Balance	8,777,893
Stock Options, Options forfeited	(71,627)
Stock Options, Options exercised	(917,383)
Stock Options, Ending Balance	7,788,883	8,777,893
Stock Options, Vested and Exercisable	4,844,757
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning balance	$ 5.36
Weighted Average Exercise Price, Options forfeited	2
Weighted Average Exercise Price, Options exercised	1.21
Weighted Average Exercise Price, Outstanding Ending balance	$ 5.87	$ 5.36
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 42,691	$ 116,273
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	6 years 9 months 18 days	7 years 2 months 12 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)shares
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised	$ 7
Unrecognized compensation cost related to non-vested stock options	$ 18.9
Weighted-average period for recognition	2 years 1 month 6 days
Outstanding Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options	$ 12.2
Weighted-average period for recognition	1 year 10 months 24 days
Number of Shares, Granted | shares	234,800
Outstanding Restricted Stock Units | Employees Of Related Company
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted | shares	65,000
Employee Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options	$ 9
Weighted-average period for recognition	1 year 3 months 18 days
Number of Shares, Granted | shares	169,800
Non Employee Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options	$ 3.2
Weighted-average period for recognition	3 years 7 months 6 days

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Detail) - Outstanding Restricted Stock Units	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested, Beginning balance | shares	1,129,638
Number of Shares, Granted | shares	234,800
Number of Shares, Forfeited | shares	(35,000)
Number of Shares, Unvested, Ending balance | shares	1,329,438
Weighted-Average Grant Date Fair Value, Unvested, beginning balance | $ / shares	$ 20.51
Weighted-Average Grant Date Fair Value, Granted | $ / shares	8.60
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	17.13
Weighted-Average Grant Date Fair Value, Unvested, ending balance | $ / shares	$ 18.50

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Warrant Activity (Detail) - Outstanding Warrants	3 Months Ended
	Mar. 31, 2016shares
Warrant [Line Items]
Warrants, Beginning Balance	17,819,616
Warrants exercised	(1,929)
Warrants, Ending Balance	17,817,687
Warrants, Vested and exercisable Ending Balance	10,553,550

Acquisition of Inex Bio, Inc -

Acquisition of Inex Bio, Inc - Additional Information (Detail) - USD ($)	Mar. 30, 2015	Apr. 30, 2015	May. 31, 2012	Apr. 30, 2012	Mar. 31, 2016	Mar. 31, 2015
Asset Purchase [Line Items]
Number of shares acquired during period			57,000
Stock issued during period, value, acquisitions			$ 200,000
Outstanding shares acquired, percentage			22.20%
Percentage of fully diluted shares acquired			17.40%
Stock-based compensation expense					$ 20,535,000	$ 24,523,000
Inex Bio Holdings, LLC
Asset Purchase [Line Items]
Payments to acquire business						6,500,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Issuance of warrants in Inex Bio acquisition						22,747,000
Stock-based compensation expense						22,700,000
Cash based compensation						$ 5,400,000
Inex Bio Holdings, LLC | Common Class A
Asset Purchase [Line Items]
Warrants issued to acquire shares						2,609,520
Common stock exercise price						$ 2
Proceeds from exercise of warrants		$ 5,200,000
Other Owner Of Inex Bio Inc
Asset Purchase [Line Items]
Payments to acquire business						$ 1,500,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Issuance of warrants in Inex Bio acquisition						$ 5,170,000
Other Owner Of Inex Bio Inc | Common Class A
Asset Purchase [Line Items]
Warrants issued to acquire shares						593,072
Common stock exercise price						$ 2
Proceeds from exercise of warrants		$ 1,200,000
Inex Bio
Asset Purchase [Line Items]
Intangible assets amortize period						4 years
Cambridge Equities, L.P | Inex Bio Holdings, LLC
Asset Purchase [Line Items]
Ownership percentage of third party business						50.00%
Eragon Ventures, LLC
Asset Purchase [Line Items]
Number of shares acquired during period						220,000
Ownership percentage of third party business						50.00%
Percentage shares acquired						67.30%
Payments to acquire business						$ 1,100,000
Inex license agreement
Asset Purchase [Line Items]
Milestone payment amount						$ 0
Percentage of royalty on net sales				5.00%
Up front fee | Inex license agreement
Asset Purchase [Line Items]
License fees received				$ 300,000
Maximum | Inex license agreement
Asset Purchase [Line Items]
Milestone payment amount				$ 800,000

Acquisition of Inex Bio, Inc 52

Acquisition of Inex Bio, Inc - Summary of Purchase Price Paid to Inex Bio (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	3 Months Ended
	Mar. 31, 2015USD ($)
Asset Purchase [Line Items]
Cash paid by InexBio Holdings, LLC	$ 1,100
Cash paid by Company	1,482
Fair value of warrants	5,170
Aggregate purchase price	$ 7,752

Acquisition of Inex Bio, Inc 53

Acquisition of Inex Bio, Inc - Summary of Assets and Liabilities Assumed (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	Mar. 31, 2015USD ($)
Asset Purchase [Line Items]
Cash	$ 763
Intangible assets—reacquired rights of Company technology	8,636
Other assets	42
Investment in Inex Bio	(221)
Deferred tax liability	(1,467)
Accounts payable	(1)
Total assets acquired and liabilities assumed	$ 7,752

Acquisition of Inex Bio, Inc 54

Acquisition of Inex Bio, Inc - Summary of Assets and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Mar. 31, 2015
Technology License
Asset Purchase [Line Items]
Intangible asset related to deferred tax liability	$ 1.5	$ 1.5

Acquisition of Inex Bio, Inc 55

Acquisition of Inex Bio, Inc - Summary of Net Consideration Paid to Holdings (Detail) - Inex Bio Holdings, LLC $ in Thousands	3 Months Ended
	Mar. 31, 2015USD ($)
Asset Purchase [Line Items]
Cash	$ 6,518
Fair value of warrants	22,747
Less cash paid to acquire shares in Inex Bio	(1,100)
Aggregate purchase price	$ 28,165

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax [Line Items]
Federal statutory tax rate	34.00%
Company's effective tax rate	0.00%
Tax benefit	$ 52,000	$ 0
Tax benefit in other comprehensive income	300,000	0
Korea
Income Tax [Line Items]
Tax benefit	$ 100,000	$ 0